Four questions come up constantly about sermorelin and none of them needs a long answer. One has a precise figure measured in people. The other three have never been studied at all, and saying so plainly is more useful than the confident guesses that fill the gap.
How long does sermorelin stay in your system?
About four minutes. A 1994 study infused GHRH-(1-29)-NH2 — the exact molecule sermorelin is — into ten normal men and measured a disappearance half-time of 4.3 minutes, give or take 1.4 [1]. The same study measured 6.7 minutes for a version carrying a single D-Ala2 substitution — one amino acid swapped, and the molecule lasts half again as long. That is the lever every longer-acting analog pulls, in one form or another.
Four minutes sounds like nothing, and it is the entire design of the drug. Sermorelin is a signal, not a supply: it asks the pituitary for a pulse and then gets out of the way. The 1997 adult trial recorded growth hormone rising within ten minutes of the injection and staying up for about two hours [2]. So the drug is gone long before the effect is, and the two numbers answer different questions. If someone quotes you a half-life measured in hours, they are describing the pulse rather than the peptide.
It also explains why it is dosed at bedtime: a four-minute signal has to be timed to land when the pituitary is already inclined to release. And it is the whole reason longer-acting analogs exist — CJC-1295 with its albumin-binding complex was measured at 5.8 to 8.1 days, which is a different drug in practice rather than a stronger version of the same one.
Does sermorelin cause hair loss?
Nothing published addresses it. On September 15, 2026 a PubMed search for sermorelin together with hair or alopecia returned zero records [3].
That zero is worth one sentence of scrutiny, because a search that finds nothing and a search that is broken look identical. The same terms return 115 records for somatropin, 89 for growth hormone generally and 830 for testosterone. The query works, and it works on growth hormone drugs specifically. Nobody has asked the question about this one.
What that leaves is reasoning rather than evidence, and reasoning is worth less than it sounds here. The 1997 trial measured skin thickness and found it improved; it did not measure hair [2]. If you notice hair changes on sermorelin there is no published base rate to compare against, which is a reason to tell a prescriber rather than to look it up.
Can you drink alcohol on sermorelin?
No study has examined it. A search for sermorelin with alcohol or ethanol returns eleven records, and reading all eleven is the point: not one is about alcohol [3]. They match because the word appears in a buffer recipe for capillary electrophoresis, in VIP-receptor pharmacology, in mouse tumor work. A count alone would have said eleven studies exist. None does.
The nearest relevant fact is indirect and does not settle anything: alcohol affects sleep architecture, and sermorelin is dosed at night precisely because growth hormone release tracks the first hours of deep sleep. Whether that interaction matters at ordinary drinking levels is exactly what has not been measured. Ask a prescriber, who will at least know what else you are taking.
Does sermorelin make you tired?
Also unstudied as a side effect, and the zero is controlled the same way. Sermorelin returns no records alongside somnolence, drowsiness, sleepiness or fatigue, while somatropin returns 390 for the same terms [3].
The closest thing to an answer runs the other direction. The one placebo-controlled adult trial measured sleep quality through a questionnaire and found it unchanged in both the men and the women [2] — the sleep claim and what the wider literature does to it goes through that result properly. A trial that asked about sleep and found no change is not the same as a trial that looked for daytime drowsiness, but it is the only thing in the record that touches the question at all.
Why three of four answers are empty
Sermorelin has one placebo-controlled adult trial, in nineteen people, and no current FDA label to collect adverse events against. A drug with a marketed label accumulates decades of reports on questions nobody designed a study for; a compounded drug with a discontinued approval accumulates none. That is the structural reason, and what the trials did report, including the cancer question is where the positive safety record lives.
An absence of evidence is not a finding of safety, and it is not a finding of harm either. It means the honest answer to three of these four questions is that nobody knows, and that a prescriber who knows your history is better placed to guess than a search result is.